ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
BMS talks up Celgene merger to divert Opdivo disappointment fiercepharma
January 28, 2019In the wake of bad news from its closely watched immuno-oncology portfolio, Bristol-Myers Squibb executives did their best Thursday to talk up the six near-term product launches they’re expecting from the company's?$74 billion merger with Celgene. But the
Pharma Sources Insight July 2025
